In melanoma patients treated with anti-PD-1 immunotherapy, high tumor clonal mutation load was associated with improved overall survival and higher TCR-clonality (less diverse repertoire) predicted response to anti-PD-1 immunotherapy [49, 50]. The gene discussed is PDCD1; the disease is melanoma.